United States Court of Appeals for the Federal Circuit Denied Eisai/ Helsinn rehearing request so formulation patent claims covering ALOXI are not valid and are therefore not infringed by Teva's generic palonosetron product. Helsinn and Eisai are disappointed with the court’s ruling.
Is there a Helsinn company board? I'd like to hear about the cool strategies they have in place for this and propelling Akynzeo, and the enthusiasm of their representatives...
